APA (7th ed.) Citation

AR, B., FF, L., P, U., NM, R., N, K., PP, J., . . . S, O. (2025). Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. Cancer immunology, immunotherapy : CII, 74(7), 227. https://doi.org/10.1007/s00262-025-04081-5

Chicago Style (17th ed.) Citation

AR, Bopp, et al. "Inhibition of Head and Neck Squamous Cell Carcinoma by Bruton's Tyrosine Kinase Inhibitor Ibrutinib Is Associated with Reduction of Immunosuppressive T Cells." Cancer Immunology, Immunotherapy : CII 74, no. 7 (2025): 227. https://doi.org/10.1007/s00262-025-04081-5.

MLA (9th ed.) Citation

AR, Bopp, et al. "Inhibition of Head and Neck Squamous Cell Carcinoma by Bruton's Tyrosine Kinase Inhibitor Ibrutinib Is Associated with Reduction of Immunosuppressive T Cells." Cancer Immunology, Immunotherapy : CII, vol. 74, no. 7, 2025, p. 227, https://doi.org/10.1007/s00262-025-04081-5.